Over the past few years, repetitive transcranial magnetic stimulation (rTMS) has emerged as a groundbreaking approach for treating mental health and neurological disorders. Initially used as a novel treatment for major depressive disorder (MDD), rTMS has grown into an important tool in neuromodulation, offering new hope for patients who have not responded to traditional therapies. Its applications are expanding beyond depression, with exciting potential in treating anxiety, chronic pain, and neurological diseases like Alzheimer’s and Parkinson’s. In this article, we will explore the evolution of rTMS, its increasing adoption, and its potential for revolutionizing non-invasive treatments.
Over the past year, Boston Scientific acquisitions have been a crucial part of the company’s strategy to deepen and enhance its portfolio. Unlike some competitors such as Johnson & Johnson, who diversify into new areas, Boston Scientific has focused on strengthening its existing capabilities. This approach allows the company to maintain leadership in high-growth markets while expanding its product offerings. This article will explore the key acquisitions that have fueled Boston Scientific’s growth and examine how they are shaping the future of the company.
As we kick off 2025, strategic planning is at the forefront for companies across the medtech industry. Corporate leaders, investors, and innovators are all asking: Which medtech segments are growing the fastest, and how can we position ourselves to capitalize on these emerging opportunities? In this edition, we examine the five fastest-growing medtech segments that are poised to dominate in 2025 based on the latest trends and data:
Under the direction of CEO and Founder Young Juhn, Wellysis is transforming healthcare with its innovative bio-sensing technology, designed to make remote patient monitoring seamless, effective, and accessible. By leveraging cutting-edge semiconductor technology originally developed at Samsung, Wellysis offers a solution that combines comfort, precision, and scalability, aiming to redefine how we monitor and maintain health at home.
Surgical treatments for benign prostatic hyperplasia (BPH) are becoming an increasingly vital part of managing BPH, a condition that affects millions of men globally. As men age, the enlargement of the prostate often leads to lower urinary tract symptoms (LUTS) that can severely impact daily life. With the prevalence of BPH rising significantly in older men—affecting nearly 50% of men in their 60s and 90% of those in their 80s—the demand for effective treatments is growing. While medications remain the first-line therapy, more men are requiring surgical interventions as the disease progresses. In this article, we will explore the advancements in surgical treatments for BPH, the increasing variety of options available, and the evolving landscape of BPH management.
Renal denervation is a minimally invasive procedure designed to treat hypertension by targeting the renal nerves around the kidneys, which play a crucial role in regulating blood pressure. The procedure works by disrupting nerve activity that contributes to high blood pressure, leading to sustained reductions.
While it might seem unlikely, the stage for this disruption was set during an episode of The Dr. Oz Show. Semaglutide, Novo Nordisk’s GLP-1 receptor agonist, was initially developed for diabetes management and later explored for its potential to treat Alzheimer’s and dementia. However, it was on Dr. Oz’s popular talk show that the weight loss properties of the drug—marketed under the brand name Ozempic—became the focus, sparking a viral craze that would ripple across the healthcare industry.
Reach Neuro’s journey began with a shared vision: to restore independence and improve the quality of life for stroke survivors living with chronic motor deficits. Co-Founder Marco Capogrosso’s pioneering work on spinal cord stimulation, which initially focused on lower limb recovery for spinal cord injury patients, laid the scientific groundwork for the company. “What makes stroke unique is that the damage is in the brain, not the spinal cord,” explained Powell. “The circuits we’re stimulating are intact, making stroke an ideal model for targeted spinal stimulation.” This insight led the team to explore how spinal cord stimulation could be adapted to upper-limb movement for stroke patients.
This market snapshot from Life Science Intelligence provides an analysis of the global market for coronary angiography catheters and guidewires. These devices are essential to perform coronary angiography, a minimally invasive medical procedure used to visualize blood flow, identify blockages and narrowing of the coronary arteries. Devices covered within the scope of this analysis include coronary angiography catheters and coronary angiography guidewires.
MALCOVA’s journey began with a critical observation: existing breast cancer imaging technologies fell short for women with dense breast tissue, leaving a significant gap in early cancer detection. “There’s a major unmet need in breast cancer imaging,” shared Ghazi. “Our company was founded when the perfect alignment of that need met a groundbreaking innovation in imaging technology.” Ghazi originally supported the company in a limited role while working full-time elsewhere. Seeing MALCOVA’s transformative potential, she soon committed fully, becoming a Co-Founder. “I became completely committed when I saw the potential for real clinical impact,” she recalled.
